ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics (ESPR) incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion had reported earnings of 34 cents per share.Esperion generated total revenues of $65 million in the first quarter, reflecting a 53% year-over-year decline. The decrease was due to a one-time settlement-related milestone payment received from Daiichi Sankyo Europe (DSE) in the first quarter of 2024. However, ...